$AVRW is set to have a record breaking sales and revenue

New Post Public Reply Private Reply Replies (0) Message Board
Lee Adams
210
$AVRW is set to have a record breaking sales and revenue growth year in 2024 based on all the very positive groundwork that has been laid to date. The company's Seratopoical Revolution brand has clearly been demonstrated as top quality in terms of its formulations and performance, especially with the very high level endorsements that have been presented. Additionally, with the Federal interest rates set to begin a cutting phase in the months ahead, the timing is ideal for stocks like AVRW to appreciate in pps value.

$AVRW Feature: Media Grabbing Seratopical Revolution Skin Care Line, Personal Choice of Nicole Kidman for Years, Now Directly Recommended by LeadingLA Plastic Surgeon for Superior Anti-Aging Results
December 12, 2023
https://news.columbusnewsonline.com/story/478...um=twitter

From this article:

– Proprietary Nutraceutical & Topical Delivery Systems for Wellness and Anti-Aging Beauty Product Lines.

– Company Currently Holds 15 Patents.

– Seratopical Revolution Skin Care Products are Promoted by the Company’s Global Brand Ambassador and Strategic Partner Nicole Kidman.

– LA-Based Facial Plastic Surgeon Dr. Michael Persky Directly Supporting Latest Seratopical DNA Complex Product.

– Media Exposure in Top-Tier Publications Including CNN Underscored, Page Six, PEOPLE Magazine, and More.

– Q3 Net Revenue Increased Sequentially from Q2 2023.

– Sales Expected to Increase Significantly During Q4 and Into 2024.

– Gross Margin Increased 80 Basis Points Quarter-to-Quarter with Further Expansion Expected in Q4.

– Upcoming Launch of New Beauty Product Releases &New Marketing Initiatives.

– Latest Sales Results Show Accelerating Strength via New Marketing Campaigns.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Investors Urged to Act as Lawsuit Against Everus Builds

Updated Category News Views 97

Investigation of Claims Against Everus Construction Group Faruqi & Faruqi, LLP, a well-respected national securities law firm, has initiated an investigation into potential claims associated with Everus Construction Group, Inc. (NYSE: ECG). The firm specializes in shareholder rights and is aiming to provide support to affected investors after concerning revelations about...

Continue Reading
Heilongjiang Forum 2025: Elevating Macao's Global Tourism Standing

Updated Category News Views 107

Global Tourism Economy Forum 2025: A Landmark Event The Global Tourism Economy Forum (GTEF) made its notable debut outside of Macao by hosting the 2025 edition in Heilongjiang province, China. This forum gathered influential figures from the tourism sector and various related industries, fostering discussions aimed at exploring new avenues for cooperation and growth....

Continue Reading
Nextracker and T1 Energy Collaboration Drives Solar Growth

Updated Category News Views 198

Nextracker and T1 Energy Join Forces to Strengthen Solar Production Nextracker Inc. (NASDAQ: NXT) has recently established a partnership with T1 Energy Inc. (NYSE: TE) aimed at revolutionizing solar manufacturing. This collaboration will see the integration of Nextracker's cutting-edge steel module frame technology into T1 Energy's upcoming solar manufacturing plant,...

Continue Reading
Nathan Ballentine Steps In as Regional VP at New American Funding

Updated Category News Views 175

New Leadership at New American Funding New American Funding (NAF), a prominent independent mortgage lender, has announced a significant appointment. Nathan Ballentine is joining the team as the Regional Vice President, where he will play a pivotal role in propelling growth and development within the state. His expertise will be crucial as the company seeks to deepen its...

Continue Reading
CSL Behring Secures Approval for ANDEMBRY® in Japan

Updated Category News Views 341

CSL Behring's Recent Approval for ANDEMBRY® CSL Behring has announced a significant medical milestone with the approval of ANDEMBRY® (garadacimab) subcutaneous (S.C.) injection 200mg pens in Japan. This groundbreaking therapy is a first-in-class monoclonal antibody specifically designed to inhibit activated Factor XII (FXIIa), a crucial initiator in the hereditary...

Continue Reading